Receipt of Disease-Modifying Antirheumatic Drugs Among Patients With Rheumatoid Arthritis in Medicare Managed Care Plans | Zendy

Gabriela Schmajuk | Zendy; Amal N. Trivedi | Zendy; Daniel H. Solomon | Zendy; Edward Yelin | Zendy; Laura Trupin | Zendy; Eliza F. Chakravarty | Zendy; Jinoos Yazdany | Zendy

Open Access

Receipt of Disease-Modifying Antirheumatic Drugs Among Patients With Rheumatoid Arthritis in Medicare Managed Care Plans

Author(s) -

Gabriela Schmajuk,

Amal N. Trivedi,

Daniel H. Solomon,

Edward Yelin,

Laura Trupin,

Eliza F. Chakravarty,

Jinoos Yazdany

Publication year - 2011

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.2011.67

Subject(s) - medicine , rheumatoid arthritis , logistic regression , receipt , confidence interval , context (archaeology) , odds ratio , health plan , managed care , physical therapy , health care , paleontology , world wide web , computer science , economics , biology , economic growth

In 2005, the Healthcare Effectiveness Data and Information Set (HEDIS) introduced a quality measure to assess the receipt of disease-modifying antirheumatic drugs (DMARDs) among patients with rheumatoid arthritis (RA).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research